Time Frame |
Adverse events (AEs) are collected from first dose of study treatment until end of study treatment plus 30 days post treatment. AEs reported in this record are from first dose of study treatment until data cutoff for primary analysis (22-Mar-2018).
|
Adverse Event Reporting Description |
Any sign or symptom that occurs during the study treatment plus the 30 days post treatment
|
|
Arm/Group Title
|
EGF816 75 mg (Phase I Part)
|
EGF816 100 mg (Phase I Part)
|
EGF816 150 mg (Phase I Part)
|
EGF816 200 mg (Phase I Part)
|
EGF816 225 mg (Phase I Part)
|
EGF816 300 mg (Phase I Part)
|
EGF816 350 mg (Phase I Part)
|
EGF816 150 mg (Phase II Part)
|
All Subjects
|
Arm/Group Description |
Participants with locally advanced ...
|
Participants with locally advanced ...
|
Participants with locally advanced ...
|
Participants with locally advanced ...
|
Participants with locally advanced ...
|
Participants with locally advanced ...
|
Participants with locally advanced ...
|
Treatment naïve participants with l...
|
All subjects
|
Arm/Group Description |
Participants with locally advanced or metastatic NSCLC harboring specific EGFR mutations were administered with EGF816 75 mg orally once a day as continuous daily dosing in each cycle (of 28 days) during Phase I part of the study.
|
Participants with locally advanced or metastatic NSCLC harboring specific EGFR mutations were administered with EGF816 100 mg orally once a day as continuous daily dosing in each cycle (of 28 days) during Phase I part of the study.
|
Participants with locally advanced or metastatic NSCLC harboring specific EGFR mutations were administered with EGF816 150 mg orally once a day as continuous daily dosing in each cycle (of 28 days) during Phase I part of the study.
|
Participants with locally advanced or metastatic NSCLC harboring specific EGFR mutations were administered with EGF816 200 mg orally once a day as continuous daily dosing in each cycle (of 28 days) during Phase I part of the study.
|
Participants with locally advanced or metastatic NSCLC harboring specific EGFR mutations were administered with EGF816 225 mg orally once a day as continuous daily dosing in each cycle (of 28 days) during Phase I part of the study.
|
Participants with locally advanced or metastatic NSCLC harboring specific EGFR mutations were administered with EGF816 300 mg orally once a day as continuous daily dosing in each cycle (of 28 days) during Phase I part of the study.
|
Participants with locally advanced or metastatic NSCLC harboring specific EGFR mutations were administered with EGF816 350 mg orally once a day as continuous daily dosing in each cycle (of 28 days) during Phase I part of the study.
|
Treatment naïve participants with locally advanced or metastatic NSCLC harboring EGFR mutations were administered with 150 mg orally once a day as continuous daily dosing in each cycle (of 28 days) during Phase II part of the study.
|
All subjects
|
|
|
EGF816 75 mg (Phase I Part)
|
EGF816 100 mg (Phase I Part)
|
EGF816 150 mg (Phase I Part)
|
EGF816 200 mg (Phase I Part)
|
EGF816 225 mg (Phase I Part)
|
EGF816 300 mg (Phase I Part)
|
EGF816 350 mg (Phase I Part)
|
EGF816 150 mg (Phase II Part)
|
All Subjects
|
|
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Total |
3/17 (17.65%) |
1/38 (2.63%) |
7/73 (9.59%) |
0/8 (0.00%) |
6/28 (21.43%) |
0/5 (0.00%) |
1/11 (9.09%) |
3/45 (6.67%) |
21/225 (9.33%) |
|
|
EGF816 75 mg (Phase I Part)
|
EGF816 100 mg (Phase I Part)
|
EGF816 150 mg (Phase I Part)
|
EGF816 200 mg (Phase I Part)
|
EGF816 225 mg (Phase I Part)
|
EGF816 300 mg (Phase I Part)
|
EGF816 350 mg (Phase I Part)
|
EGF816 150 mg (Phase II Part)
|
All Subjects
|
|
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Total |
7/17 (41.18%) |
10/38 (26.32%) |
37/73 (50.68%) |
1/8 (12.50%) |
16/28 (57.14%) |
4/5 (80.00%) |
5/11 (45.45%) |
10/45 (22.22%) |
90/225 (40.00%) |
Blood and lymphatic system disorders |
|
|
|
|
|
|
|
|
|
Anaemia |
1/17 (5.88%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
2/225 (0.89%) |
Febrile neutropenia |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Cardiac disorders |
|
|
|
|
|
|
|
|
|
Atrial fibrillation |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Atrial tachycardia |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Cardiac failure |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Pericardial effusion |
1/17 (5.88%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
2/225 (0.89%) |
Ear and labyrinth disorders |
|
|
|
|
|
|
|
|
|
Vertigo |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Gastrointestinal disorders |
|
|
|
|
|
|
|
|
|
Diarrhoea |
0/17 (0.00%) |
0/38 (0.00%) |
2/73 (2.74%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
2/45 (4.44%) |
5/225 (2.22%) |
Duodenal ulcer |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Enteritis |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
1/11 (9.09%) |
0/45 (0.00%) |
1/225 (0.44%) |
Enterocolitis |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Gastrointestinal haemorrhage |
0/17 (0.00%) |
0/38 (0.00%) |
2/73 (2.74%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
2/225 (0.89%) |
Haemorrhagic ascites |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Ileus |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Pancreatitis |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Stomatitis |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Upper gastrointestinal haemorrhage |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
General disorders |
|
|
|
|
|
|
|
|
|
Face oedema |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Fatigue |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Non-cardiac chest pain |
1/17 (5.88%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Oedema peripheral |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Pyrexia |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
1/5 (20.00%) |
0/11 (0.00%) |
2/45 (4.44%) |
3/225 (1.33%) |
Hepatobiliary disorders |
|
|
|
|
|
|
|
|
|
Cholestasis |
0/17 (0.00%) |
1/38 (2.63%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Hepatic failure |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Infections and infestations |
|
|
|
|
|
|
|
|
|
Appendicitis |
0/17 (0.00%) |
1/38 (2.63%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Bacteraemia |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Bronchitis |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
1/225 (0.44%) |
Empyema |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Hepatitis B reactivation |
0/17 (0.00%) |
1/38 (2.63%) |
0/73 (0.00%) |
0/8 (0.00%) |
2/28 (7.14%) |
0/5 (0.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
4/225 (1.78%) |
Lung infection |
0/17 (0.00%) |
2/38 (5.26%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
3/225 (1.33%) |
Meningitis |
0/17 (0.00%) |
2/38 (5.26%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
2/225 (0.89%) |
Perihepatic abscess |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
1/5 (20.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Pneumonia |
1/17 (5.88%) |
2/38 (5.26%) |
6/73 (8.22%) |
0/8 (0.00%) |
4/28 (14.29%) |
1/5 (20.00%) |
3/11 (27.27%) |
0/45 (0.00%) |
17/225 (7.56%) |
Pneumonia bacterial |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
2/225 (0.89%) |
Pneumonia influenzal |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Pyelonephritis |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
1/225 (0.44%) |
Sepsis |
1/17 (5.88%) |
0/38 (0.00%) |
3/73 (4.11%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
4/225 (1.78%) |
Septic shock |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Viral infection |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Injury, poisoning and procedural complications |
|
|
|
|
|
|
|
|
|
Accidental overdose |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Femur fracture |
0/17 (0.00%) |
0/38 (0.00%) |
2/73 (2.74%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
2/225 (0.89%) |
Joint dislocation |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
1/225 (0.44%) |
Spinal compression fracture |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
1/8 (12.50%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Spinal fracture |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
1/11 (9.09%) |
0/45 (0.00%) |
1/225 (0.44%) |
Subdural haematoma |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
1/8 (12.50%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
3/225 (1.33%) |
Investigations |
|
|
|
|
|
|
|
|
|
Hepatitis B DNA assay positive |
0/17 (0.00%) |
1/38 (2.63%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Metabolism and nutrition disorders |
|
|
|
|
|
|
|
|
|
Decreased appetite |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
3/225 (1.33%) |
Dehydration |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
1/11 (9.09%) |
0/45 (0.00%) |
1/225 (0.44%) |
Fluid overload |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Hypoglycaemia |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Musculoskeletal and connective tissue disorders |
|
|
|
|
|
|
|
|
|
Back pain |
1/17 (5.88%) |
1/38 (2.63%) |
2/73 (2.74%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
5/225 (2.22%) |
Bone pain |
1/17 (5.88%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Muscular weakness |
0/17 (0.00%) |
1/38 (2.63%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Pain in extremity |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
|
|
|
|
|
|
|
|
B-cell lymphoma |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
1/11 (9.09%) |
0/45 (0.00%) |
1/225 (0.44%) |
Cancer pain |
1/17 (5.88%) |
1/38 (2.63%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
2/225 (0.89%) |
Lymphangiosis carcinomatosa |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Metastases to meninges |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Pancreatic carcinoma |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Tumour pain |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Nervous system disorders |
|
|
|
|
|
|
|
|
|
Cerebrovascular accident |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Dizziness |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
2/28 (7.14%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
3/225 (1.33%) |
Hydrocephalus |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Paraesthesia |
1/17 (5.88%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Seizure |
0/17 (0.00%) |
0/38 (0.00%) |
2/73 (2.74%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
1/11 (9.09%) |
0/45 (0.00%) |
3/225 (1.33%) |
Spinal cord compression |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Psychiatric disorders |
|
|
|
|
|
|
|
|
|
Confusional state |
0/17 (0.00%) |
1/38 (2.63%) |
3/73 (4.11%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
4/225 (1.78%) |
Renal and urinary disorders |
|
|
|
|
|
|
|
|
|
Acute kidney injury |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
1/11 (9.09%) |
0/45 (0.00%) |
2/225 (0.89%) |
Urinary retention |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Reproductive system and breast disorders |
|
|
|
|
|
|
|
|
|
Vaginal prolapse |
0/17 (0.00%) |
1/38 (2.63%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Respiratory, thoracic and mediastinal disorders |
|
|
|
|
|
|
|
|
|
Acute respiratory distress syndrome |
1/17 (5.88%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Choking |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Chronic obstructive pulmonary disease |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Dyspnoea |
1/17 (5.88%) |
1/38 (2.63%) |
4/73 (5.48%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
7/225 (3.11%) |
Haemoptysis |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Interstitial lung disease |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Pneumonia aspiration |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
2/225 (0.89%) |
Pneumonitis |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
3/225 (1.33%) |
Pneumothorax |
0/17 (0.00%) |
0/38 (0.00%) |
3/73 (4.11%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
3/225 (1.33%) |
Pulmonary haemorrhage |
1/17 (5.88%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
2/225 (0.89%) |
Pulmonary oedema |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
1/5 (20.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Skin and subcutaneous tissue disorders |
|
|
|
|
|
|
|
|
|
Rash maculo-papular |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Vascular disorders |
|
|
|
|
|
|
|
|
|
Aortic dissection |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
1/225 (0.44%) |
Hypertension |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Lymphoedema |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Term from vocabulary, MedDRA (21.0)
Indicates events were collected by systematic assessment
|
|
Frequency Threshold for Reporting Other Adverse Events
|
5%
|
|
EGF816 75 mg (Phase I Part)
|
EGF816 100 mg (Phase I Part)
|
EGF816 150 mg (Phase I Part)
|
EGF816 200 mg (Phase I Part)
|
EGF816 225 mg (Phase I Part)
|
EGF816 300 mg (Phase I Part)
|
EGF816 350 mg (Phase I Part)
|
EGF816 150 mg (Phase II Part)
|
All Subjects
|
|
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Total |
17/17 (100.00%) |
36/38 (94.74%) |
72/73 (98.63%) |
8/8 (100.00%) |
28/28 (100.00%) |
5/5 (100.00%) |
11/11 (100.00%) |
41/45 (91.11%) |
218/225 (96.89%) |
Blood and lymphatic system disorders |
|
|
|
|
|
|
|
|
|
Anaemia |
1/17 (5.88%) |
4/38 (10.53%) |
10/73 (13.70%) |
0/8 (0.00%) |
7/28 (25.00%) |
3/5 (60.00%) |
4/11 (36.36%) |
2/45 (4.44%) |
31/225 (13.78%) |
Disseminated intravascular coagulation |
1/17 (5.88%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Eosinophilia |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
1/8 (12.50%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
2/225 (0.89%) |
Immune thrombocytopenic purpura |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
1/5 (20.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Neutropenia |
0/17 (0.00%) |
1/38 (2.63%) |
4/73 (5.48%) |
1/8 (12.50%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
3/45 (6.67%) |
10/225 (4.44%) |
Thrombocytopenia |
0/17 (0.00%) |
2/38 (5.26%) |
2/73 (2.74%) |
1/8 (12.50%) |
0/28 (0.00%) |
1/5 (20.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
6/225 (2.67%) |
Cardiac disorders |
|
|
|
|
|
|
|
|
|
Angina pectoris |
0/17 (0.00%) |
2/38 (5.26%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
2/225 (0.89%) |
Atrial fibrillation |
1/17 (5.88%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
2/225 (0.89%) |
Cardiac failure congestive |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
1/5 (20.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Left ventricular dysfunction |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
1/5 (20.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Sinus tachycardia |
0/17 (0.00%) |
0/38 (0.00%) |
2/73 (2.74%) |
0/8 (0.00%) |
0/28 (0.00%) |
1/5 (20.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
3/225 (1.33%) |
Ear and labyrinth disorders |
|
|
|
|
|
|
|
|
|
Ear haemorrhage |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
1/11 (9.09%) |
0/45 (0.00%) |
1/225 (0.44%) |
Eye disorders |
|
|
|
|
|
|
|
|
|
Dry eye |
0/17 (0.00%) |
1/38 (2.63%) |
4/73 (5.48%) |
0/8 (0.00%) |
1/28 (3.57%) |
1/5 (20.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
8/225 (3.56%) |
Eye discharge |
1/17 (5.88%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Lacrimation increased |
1/17 (5.88%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Ocular hyperaemia |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
1/11 (9.09%) |
0/45 (0.00%) |
2/225 (0.89%) |
Vision blurred |
0/17 (0.00%) |
0/38 (0.00%) |
5/73 (6.85%) |
2/8 (25.00%) |
2/28 (7.14%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
9/225 (4.00%) |
Gastrointestinal disorders |
|
|
|
|
|
|
|
|
|
Abdominal discomfort |
1/17 (5.88%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Abdominal distension |
1/17 (5.88%) |
1/38 (2.63%) |
3/73 (4.11%) |
0/8 (0.00%) |
2/28 (7.14%) |
0/5 (0.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
8/225 (3.56%) |
Abdominal pain |
2/17 (11.76%) |
2/38 (5.26%) |
4/73 (5.48%) |
0/8 (0.00%) |
3/28 (10.71%) |
0/5 (0.00%) |
1/11 (9.09%) |
1/45 (2.22%) |
13/225 (5.78%) |
Abdominal pain upper |
1/17 (5.88%) |
1/38 (2.63%) |
2/73 (2.74%) |
0/8 (0.00%) |
1/28 (3.57%) |
1/5 (20.00%) |
2/11 (18.18%) |
3/45 (6.67%) |
11/225 (4.89%) |
Aphthous ulcer |
0/17 (0.00%) |
1/38 (2.63%) |
2/73 (2.74%) |
0/8 (0.00%) |
0/28 (0.00%) |
1/5 (20.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
4/225 (1.78%) |
Cheilitis |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
2/11 (18.18%) |
0/45 (0.00%) |
2/225 (0.89%) |
Constipation |
2/17 (11.76%) |
9/38 (23.68%) |
16/73 (21.92%) |
1/8 (12.50%) |
4/28 (14.29%) |
0/5 (0.00%) |
0/11 (0.00%) |
2/45 (4.44%) |
34/225 (15.11%) |
Diarrhoea |
4/17 (23.53%) |
13/38 (34.21%) |
29/73 (39.73%) |
4/8 (50.00%) |
17/28 (60.71%) |
5/5 (100.00%) |
9/11 (81.82%) |
17/45 (37.78%) |
98/225 (43.56%) |
Dry mouth |
0/17 (0.00%) |
1/38 (2.63%) |
5/73 (6.85%) |
0/8 (0.00%) |
2/28 (7.14%) |
1/5 (20.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
9/225 (4.00%) |
Dyspepsia |
1/17 (5.88%) |
0/38 (0.00%) |
5/73 (6.85%) |
0/8 (0.00%) |
3/28 (10.71%) |
1/5 (20.00%) |
1/11 (9.09%) |
3/45 (6.67%) |
14/225 (6.22%) |
Enterocolitis |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
1/11 (9.09%) |
0/45 (0.00%) |
3/225 (1.33%) |
Flatulence |
0/17 (0.00%) |
0/38 (0.00%) |
2/73 (2.74%) |
0/8 (0.00%) |
0/28 (0.00%) |
1/5 (20.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
4/225 (1.78%) |
Gastritis |
1/17 (5.88%) |
0/38 (0.00%) |
1/73 (1.37%) |
1/8 (12.50%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
4/225 (1.78%) |
Gastrooesophageal reflux disease |
0/17 (0.00%) |
3/38 (7.89%) |
4/73 (5.48%) |
0/8 (0.00%) |
1/28 (3.57%) |
1/5 (20.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
10/225 (4.44%) |
Haemorrhoids |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
1/11 (9.09%) |
2/45 (4.44%) |
4/225 (1.78%) |
Ileus |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
1/11 (9.09%) |
0/45 (0.00%) |
1/225 (0.44%) |
Nausea |
4/17 (23.53%) |
7/38 (18.42%) |
13/73 (17.81%) |
2/8 (25.00%) |
10/28 (35.71%) |
2/5 (40.00%) |
3/11 (27.27%) |
5/45 (11.11%) |
46/225 (20.44%) |
Odynophagia |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
1/5 (20.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
2/225 (0.89%) |
Oral pain |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
1/11 (9.09%) |
1/45 (2.22%) |
2/225 (0.89%) |
Stomatitis |
8/17 (47.06%) |
9/38 (23.68%) |
19/73 (26.03%) |
3/8 (37.50%) |
11/28 (39.29%) |
1/5 (20.00%) |
3/11 (27.27%) |
11/45 (24.44%) |
65/225 (28.89%) |
Vomiting |
5/17 (29.41%) |
6/38 (15.79%) |
9/73 (12.33%) |
0/8 (0.00%) |
8/28 (28.57%) |
1/5 (20.00%) |
2/11 (18.18%) |
2/45 (4.44%) |
33/225 (14.67%) |
General disorders |
|
|
|
|
|
|
|
|
|
Asthenia |
1/17 (5.88%) |
1/38 (2.63%) |
4/73 (5.48%) |
0/8 (0.00%) |
1/28 (3.57%) |
1/5 (20.00%) |
1/11 (9.09%) |
1/45 (2.22%) |
10/225 (4.44%) |
Chest discomfort |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
2/28 (7.14%) |
0/5 (0.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
4/225 (1.78%) |
Chills |
0/17 (0.00%) |
3/38 (7.89%) |
2/73 (2.74%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
2/11 (18.18%) |
0/45 (0.00%) |
8/225 (3.56%) |
Early satiety |
1/17 (5.88%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Fatigue |
8/17 (47.06%) |
7/38 (18.42%) |
21/73 (28.77%) |
3/8 (37.50%) |
8/28 (28.57%) |
3/5 (60.00%) |
3/11 (27.27%) |
5/45 (11.11%) |
58/225 (25.78%) |
Influenza like illness |
0/17 (0.00%) |
2/38 (5.26%) |
3/73 (4.11%) |
1/8 (12.50%) |
2/28 (7.14%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
8/225 (3.56%) |
Non-cardiac chest pain |
1/17 (5.88%) |
2/38 (5.26%) |
7/73 (9.59%) |
0/8 (0.00%) |
2/28 (7.14%) |
0/5 (0.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
13/225 (5.78%) |
Oedema peripheral |
1/17 (5.88%) |
5/38 (13.16%) |
11/73 (15.07%) |
2/8 (25.00%) |
1/28 (3.57%) |
2/5 (40.00%) |
0/11 (0.00%) |
3/45 (6.67%) |
25/225 (11.11%) |
Peripheral swelling |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
1/11 (9.09%) |
0/45 (0.00%) |
2/225 (0.89%) |
Pyrexia |
0/17 (0.00%) |
2/38 (5.26%) |
9/73 (12.33%) |
1/8 (12.50%) |
6/28 (21.43%) |
2/5 (40.00%) |
2/11 (18.18%) |
7/45 (15.56%) |
29/225 (12.89%) |
Xerosis |
0/17 (0.00%) |
0/38 (0.00%) |
2/73 (2.74%) |
1/8 (12.50%) |
2/28 (7.14%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
5/225 (2.22%) |
Hepatobiliary disorders |
|
|
|
|
|
|
|
|
|
Hepatic function abnormal |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
2/28 (7.14%) |
0/5 (0.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
4/225 (1.78%) |
Immune system disorders |
|
|
|
|
|
|
|
|
|
Hypersensitivity |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
1/8 (12.50%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Infections and infestations |
|
|
|
|
|
|
|
|
|
Blister infected |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
1/5 (20.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Bronchitis |
0/17 (0.00%) |
2/38 (5.26%) |
0/73 (0.00%) |
1/8 (12.50%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
3/225 (1.33%) |
Conjunctivitis |
0/17 (0.00%) |
3/38 (7.89%) |
1/73 (1.37%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
3/45 (6.67%) |
8/225 (3.56%) |
Conjunctivitis viral |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
2/5 (40.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
2/225 (0.89%) |
Folliculitis |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
1/11 (9.09%) |
1/45 (2.22%) |
3/225 (1.33%) |
Genital herpes |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
1/11 (9.09%) |
0/45 (0.00%) |
1/225 (0.44%) |
Herpes zoster |
1/17 (5.88%) |
1/38 (2.63%) |
2/73 (2.74%) |
1/8 (12.50%) |
1/28 (3.57%) |
1/5 (20.00%) |
0/11 (0.00%) |
2/45 (4.44%) |
9/225 (4.00%) |
Influenza |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
2/28 (7.14%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
2/225 (0.89%) |
Lower respiratory tract infection |
1/17 (5.88%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
1/5 (20.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
3/225 (1.33%) |
Lung infection |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
1/5 (20.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
2/225 (0.89%) |
Nasopharyngitis |
2/17 (11.76%) |
3/38 (7.89%) |
5/73 (6.85%) |
1/8 (12.50%) |
4/28 (14.29%) |
0/5 (0.00%) |
0/11 (0.00%) |
3/45 (6.67%) |
18/225 (8.00%) |
Onychomycosis |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
1/28 (3.57%) |
1/5 (20.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
2/225 (0.89%) |
Oral candidiasis |
0/17 (0.00%) |
1/38 (2.63%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
1/11 (9.09%) |
0/45 (0.00%) |
2/225 (0.89%) |
Paronychia |
1/17 (5.88%) |
3/38 (7.89%) |
12/73 (16.44%) |
2/8 (25.00%) |
4/28 (14.29%) |
1/5 (20.00%) |
4/11 (36.36%) |
3/45 (6.67%) |
30/225 (13.33%) |
Pharyngitis |
1/17 (5.88%) |
2/38 (5.26%) |
2/73 (2.74%) |
1/8 (12.50%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
8/225 (3.56%) |
Pneumonia |
0/17 (0.00%) |
1/38 (2.63%) |
3/73 (4.11%) |
0/8 (0.00%) |
2/28 (7.14%) |
0/5 (0.00%) |
1/11 (9.09%) |
1/45 (2.22%) |
8/225 (3.56%) |
Rash pustular |
1/17 (5.88%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
1/11 (9.09%) |
0/45 (0.00%) |
2/225 (0.89%) |
Respiratory tract infection |
0/17 (0.00%) |
1/38 (2.63%) |
2/73 (2.74%) |
0/8 (0.00%) |
0/28 (0.00%) |
1/5 (20.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
5/225 (2.22%) |
Rhinitis |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
1/8 (12.50%) |
1/28 (3.57%) |
1/5 (20.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
3/225 (1.33%) |
Skin infection |
0/17 (0.00%) |
1/38 (2.63%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
1/11 (9.09%) |
0/45 (0.00%) |
2/225 (0.89%) |
Tonsillitis |
1/17 (5.88%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
2/225 (0.89%) |
Tuberculosis |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
1/11 (9.09%) |
0/45 (0.00%) |
1/225 (0.44%) |
Upper respiratory tract infection |
1/17 (5.88%) |
8/38 (21.05%) |
6/73 (8.22%) |
2/8 (25.00%) |
7/28 (25.00%) |
0/5 (0.00%) |
2/11 (18.18%) |
4/45 (8.89%) |
30/225 (13.33%) |
Urinary tract infection |
2/17 (11.76%) |
3/38 (7.89%) |
4/73 (5.48%) |
2/8 (25.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
13/225 (5.78%) |
Viral upper respiratory tract infection |
0/17 (0.00%) |
1/38 (2.63%) |
1/73 (1.37%) |
1/8 (12.50%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
4/225 (1.78%) |
Wound infection |
1/17 (5.88%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Injury, poisoning and procedural complications |
|
|
|
|
|
|
|
|
|
Contusion |
0/17 (0.00%) |
3/38 (7.89%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
3/225 (1.33%) |
Face injury |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
1/8 (12.50%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Fracture |
1/17 (5.88%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Ligament sprain |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
1/11 (9.09%) |
1/45 (2.22%) |
2/225 (0.89%) |
Procedural pain |
0/17 (0.00%) |
0/38 (0.00%) |
3/73 (4.11%) |
0/8 (0.00%) |
3/28 (10.71%) |
0/5 (0.00%) |
1/11 (9.09%) |
0/45 (0.00%) |
7/225 (3.11%) |
Radius fracture |
1/17 (5.88%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Subdural haematoma |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
1/8 (12.50%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
2/225 (0.89%) |
Investigations |
|
|
|
|
|
|
|
|
|
Alanine aminotransferase increased |
2/17 (11.76%) |
4/38 (10.53%) |
4/73 (5.48%) |
0/8 (0.00%) |
2/28 (7.14%) |
0/5 (0.00%) |
1/11 (9.09%) |
3/45 (6.67%) |
16/225 (7.11%) |
Amylase increased |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
1/11 (9.09%) |
0/45 (0.00%) |
2/225 (0.89%) |
Aspartate aminotransferase increased |
2/17 (11.76%) |
2/38 (5.26%) |
4/73 (5.48%) |
0/8 (0.00%) |
3/28 (10.71%) |
0/5 (0.00%) |
1/11 (9.09%) |
4/45 (8.89%) |
16/225 (7.11%) |
Blood alkaline phosphatase increased |
0/17 (0.00%) |
2/38 (5.26%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
1/5 (20.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
5/225 (2.22%) |
Blood bilirubin increased |
0/17 (0.00%) |
1/38 (2.63%) |
1/73 (1.37%) |
0/8 (0.00%) |
1/28 (3.57%) |
1/5 (20.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
4/225 (1.78%) |
Blood creatine phosphokinase increased |
0/17 (0.00%) |
2/38 (5.26%) |
1/73 (1.37%) |
0/8 (0.00%) |
4/28 (14.29%) |
0/5 (0.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
8/225 (3.56%) |
Blood creatinine increased |
1/17 (5.88%) |
2/38 (5.26%) |
5/73 (6.85%) |
1/8 (12.50%) |
4/28 (14.29%) |
1/5 (20.00%) |
1/11 (9.09%) |
0/45 (0.00%) |
15/225 (6.67%) |
Electrocardiogram QT prolonged |
0/17 (0.00%) |
1/38 (2.63%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
2/5 (40.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
4/225 (1.78%) |
Gamma-glutamyltransferase increased |
0/17 (0.00%) |
3/38 (7.89%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
1/5 (20.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
6/225 (2.67%) |
Neutrophil count decreased |
1/17 (5.88%) |
2/38 (5.26%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
5/225 (2.22%) |
Platelet count decreased |
1/17 (5.88%) |
0/38 (0.00%) |
3/73 (4.11%) |
0/8 (0.00%) |
4/28 (14.29%) |
1/5 (20.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
10/225 (4.44%) |
Weight decreased |
0/17 (0.00%) |
1/38 (2.63%) |
3/73 (4.11%) |
0/8 (0.00%) |
4/28 (14.29%) |
0/5 (0.00%) |
2/11 (18.18%) |
0/45 (0.00%) |
10/225 (4.44%) |
Metabolism and nutrition disorders |
|
|
|
|
|
|
|
|
|
Decreased appetite |
5/17 (29.41%) |
4/38 (10.53%) |
15/73 (20.55%) |
2/8 (25.00%) |
7/28 (25.00%) |
2/5 (40.00%) |
5/11 (45.45%) |
9/45 (20.00%) |
49/225 (21.78%) |
Dehydration |
0/17 (0.00%) |
3/38 (7.89%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
1/11 (9.09%) |
0/45 (0.00%) |
5/225 (2.22%) |
Hyperglycaemia |
0/17 (0.00%) |
2/38 (5.26%) |
2/73 (2.74%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
5/225 (2.22%) |
Hyperkalaemia |
0/17 (0.00%) |
3/38 (7.89%) |
4/73 (5.48%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
1/11 (9.09%) |
1/45 (2.22%) |
10/225 (4.44%) |
Hyperuricaemia |
0/17 (0.00%) |
2/38 (5.26%) |
0/73 (0.00%) |
0/8 (0.00%) |
2/28 (7.14%) |
0/5 (0.00%) |
1/11 (9.09%) |
1/45 (2.22%) |
6/225 (2.67%) |
Hypoalbuminaemia |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
3/45 (6.67%) |
4/225 (1.78%) |
Hypocalcaemia |
0/17 (0.00%) |
1/38 (2.63%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
1/5 (20.00%) |
0/11 (0.00%) |
2/45 (4.44%) |
5/225 (2.22%) |
Hypokalaemia |
1/17 (5.88%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
3/28 (10.71%) |
0/5 (0.00%) |
1/11 (9.09%) |
3/45 (6.67%) |
8/225 (3.56%) |
Hypomagnesaemia |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
2/28 (7.14%) |
2/5 (40.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
6/225 (2.67%) |
Hyponatraemia |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
2/28 (7.14%) |
1/5 (20.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
4/225 (1.78%) |
Hypophosphataemia |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
1/28 (3.57%) |
1/5 (20.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
4/225 (1.78%) |
Musculoskeletal and connective tissue disorders |
|
|
|
|
|
|
|
|
|
Arthralgia |
1/17 (5.88%) |
6/38 (15.79%) |
8/73 (10.96%) |
0/8 (0.00%) |
2/28 (7.14%) |
0/5 (0.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
18/225 (8.00%) |
Back pain |
4/17 (23.53%) |
6/38 (15.79%) |
12/73 (16.44%) |
2/8 (25.00%) |
4/28 (14.29%) |
1/5 (20.00%) |
1/11 (9.09%) |
3/45 (6.67%) |
33/225 (14.67%) |
Bone pain |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
1/8 (12.50%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
2/225 (0.89%) |
Flank pain |
1/17 (5.88%) |
1/38 (2.63%) |
3/73 (4.11%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
6/225 (2.67%) |
Muscle spasms |
1/17 (5.88%) |
6/38 (15.79%) |
10/73 (13.70%) |
3/8 (37.50%) |
1/28 (3.57%) |
1/5 (20.00%) |
0/11 (0.00%) |
2/45 (4.44%) |
24/225 (10.67%) |
Muscular weakness |
0/17 (0.00%) |
3/38 (7.89%) |
1/73 (1.37%) |
1/8 (12.50%) |
2/28 (7.14%) |
0/5 (0.00%) |
1/11 (9.09%) |
1/45 (2.22%) |
9/225 (4.00%) |
Musculoskeletal chest pain |
1/17 (5.88%) |
8/38 (21.05%) |
4/73 (5.48%) |
1/8 (12.50%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
4/45 (8.89%) |
18/225 (8.00%) |
Myalgia |
1/17 (5.88%) |
2/38 (5.26%) |
6/73 (8.22%) |
1/8 (12.50%) |
3/28 (10.71%) |
0/5 (0.00%) |
2/11 (18.18%) |
0/45 (0.00%) |
15/225 (6.67%) |
Neck pain |
0/17 (0.00%) |
0/38 (0.00%) |
6/73 (8.22%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
2/45 (4.44%) |
8/225 (3.56%) |
Osteoporosis |
1/17 (5.88%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Pain in extremity |
1/17 (5.88%) |
4/38 (10.53%) |
8/73 (10.96%) |
0/8 (0.00%) |
2/28 (7.14%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
15/225 (6.67%) |
Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
|
|
|
|
|
|
|
|
Cancer pain |
1/17 (5.88%) |
0/38 (0.00%) |
2/73 (2.74%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
4/225 (1.78%) |
Nervous system disorders |
|
|
|
|
|
|
|
|
|
Amnesia |
0/17 (0.00%) |
1/38 (2.63%) |
0/73 (0.00%) |
1/8 (12.50%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
2/225 (0.89%) |
Aphasia |
0/17 (0.00%) |
0/38 (0.00%) |
2/73 (2.74%) |
1/8 (12.50%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
3/225 (1.33%) |
Ataxia |
0/17 (0.00%) |
1/38 (2.63%) |
1/73 (1.37%) |
1/8 (12.50%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
3/225 (1.33%) |
Cerebral haemorrhage |
1/17 (5.88%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Cognitive disorder |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
1/8 (12.50%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
2/225 (0.89%) |
Dementia |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
1/8 (12.50%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Dizziness |
4/17 (23.53%) |
5/38 (13.16%) |
7/73 (9.59%) |
1/8 (12.50%) |
4/28 (14.29%) |
2/5 (40.00%) |
1/11 (9.09%) |
0/45 (0.00%) |
24/225 (10.67%) |
Dysgeusia |
0/17 (0.00%) |
2/38 (5.26%) |
2/73 (2.74%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
2/11 (18.18%) |
4/45 (8.89%) |
11/225 (4.89%) |
Headache |
1/17 (5.88%) |
6/38 (15.79%) |
11/73 (15.07%) |
3/8 (37.50%) |
5/28 (17.86%) |
1/5 (20.00%) |
1/11 (9.09%) |
4/45 (8.89%) |
32/225 (14.22%) |
Hyperaesthesia |
0/17 (0.00%) |
2/38 (5.26%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
2/225 (0.89%) |
Hypoaesthesia |
1/17 (5.88%) |
1/38 (2.63%) |
1/73 (1.37%) |
1/8 (12.50%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
4/225 (1.78%) |
Memory impairment |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
1/8 (12.50%) |
0/28 (0.00%) |
0/5 (0.00%) |
1/11 (9.09%) |
0/45 (0.00%) |
2/225 (0.89%) |
Neuropathy peripheral |
1/17 (5.88%) |
0/38 (0.00%) |
0/73 (0.00%) |
2/8 (25.00%) |
2/28 (7.14%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
5/225 (2.22%) |
Paraesthesia |
1/17 (5.88%) |
1/38 (2.63%) |
2/73 (2.74%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
5/225 (2.22%) |
Petit mal epilepsy |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
1/8 (12.50%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Seizure |
1/17 (5.88%) |
0/38 (0.00%) |
2/73 (2.74%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
3/225 (1.33%) |
Tremor |
1/17 (5.88%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Psychiatric disorders |
|
|
|
|
|
|
|
|
|
Anxiety |
0/17 (0.00%) |
2/38 (5.26%) |
1/73 (1.37%) |
1/8 (12.50%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
5/225 (2.22%) |
Depressed mood |
1/17 (5.88%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Depression |
0/17 (0.00%) |
1/38 (2.63%) |
2/73 (2.74%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
1/11 (9.09%) |
1/45 (2.22%) |
5/225 (2.22%) |
Insomnia |
2/17 (11.76%) |
2/38 (5.26%) |
7/73 (9.59%) |
3/8 (37.50%) |
2/28 (7.14%) |
0/5 (0.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
17/225 (7.56%) |
Renal and urinary disorders |
|
|
|
|
|
|
|
|
|
Dysuria |
0/17 (0.00%) |
0/38 (0.00%) |
2/73 (2.74%) |
1/8 (12.50%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
4/225 (1.78%) |
Hypertonic bladder |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
1/8 (12.50%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Micturition urgency |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
1/8 (12.50%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Nocturia |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
1/8 (12.50%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Pollakiuria |
1/17 (5.88%) |
1/38 (2.63%) |
1/73 (1.37%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
4/225 (1.78%) |
Polyuria |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
1/8 (12.50%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Urinary incontinence |
0/17 (0.00%) |
1/38 (2.63%) |
1/73 (1.37%) |
2/8 (25.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
4/225 (1.78%) |
Urinary retention |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
2/28 (7.14%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
2/225 (0.89%) |
Reproductive system and breast disorders |
|
|
|
|
|
|
|
|
|
Pelvic pain |
1/17 (5.88%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
2/225 (0.89%) |
Vulvovaginal dryness |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
1/5 (20.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Respiratory, thoracic and mediastinal disorders |
|
|
|
|
|
|
|
|
|
Acute respiratory distress syndrome |
1/17 (5.88%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Cough |
5/17 (29.41%) |
7/38 (18.42%) |
21/73 (28.77%) |
2/8 (25.00%) |
10/28 (35.71%) |
2/5 (40.00%) |
2/11 (18.18%) |
10/45 (22.22%) |
59/225 (26.22%) |
Dry throat |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
1/5 (20.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Dysphonia |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
1/11 (9.09%) |
0/45 (0.00%) |
3/225 (1.33%) |
Dyspnoea |
6/17 (35.29%) |
1/38 (2.63%) |
12/73 (16.44%) |
0/8 (0.00%) |
8/28 (28.57%) |
1/5 (20.00%) |
1/11 (9.09%) |
2/45 (4.44%) |
31/225 (13.78%) |
Dyspnoea exertional |
0/17 (0.00%) |
0/38 (0.00%) |
2/73 (2.74%) |
1/8 (12.50%) |
2/28 (7.14%) |
0/5 (0.00%) |
1/11 (9.09%) |
2/45 (4.44%) |
8/225 (3.56%) |
Epistaxis |
0/17 (0.00%) |
1/38 (2.63%) |
6/73 (8.22%) |
0/8 (0.00%) |
2/28 (7.14%) |
2/5 (40.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
11/225 (4.89%) |
Haemoptysis |
2/17 (11.76%) |
0/38 (0.00%) |
5/73 (6.85%) |
1/8 (12.50%) |
2/28 (7.14%) |
1/5 (20.00%) |
3/11 (27.27%) |
0/45 (0.00%) |
14/225 (6.22%) |
Hiccups |
1/17 (5.88%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
2/225 (0.89%) |
Laryngeal inflammation |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
1/11 (9.09%) |
0/45 (0.00%) |
2/225 (0.89%) |
Nasal congestion |
1/17 (5.88%) |
1/38 (2.63%) |
2/73 (2.74%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
5/225 (2.22%) |
Nasal dryness |
0/17 (0.00%) |
1/38 (2.63%) |
3/73 (4.11%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
1/11 (9.09%) |
0/45 (0.00%) |
5/225 (2.22%) |
Oropharyngeal pain |
0/17 (0.00%) |
0/38 (0.00%) |
3/73 (4.11%) |
0/8 (0.00%) |
3/28 (10.71%) |
0/5 (0.00%) |
0/11 (0.00%) |
2/45 (4.44%) |
8/225 (3.56%) |
Orthopnoea |
1/17 (5.88%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Pharyngeal inflammation |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
2/28 (7.14%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
3/225 (1.33%) |
Pleural effusion |
0/17 (0.00%) |
0/38 (0.00%) |
3/73 (4.11%) |
0/8 (0.00%) |
0/28 (0.00%) |
1/5 (20.00%) |
0/11 (0.00%) |
2/45 (4.44%) |
6/225 (2.67%) |
Productive cough |
1/17 (5.88%) |
1/38 (2.63%) |
2/73 (2.74%) |
0/8 (0.00%) |
1/28 (3.57%) |
1/5 (20.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
7/225 (3.11%) |
Rhinitis allergic |
0/17 (0.00%) |
0/38 (0.00%) |
2/73 (2.74%) |
1/8 (12.50%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
4/225 (1.78%) |
Rhinorrhoea |
1/17 (5.88%) |
1/38 (2.63%) |
8/73 (10.96%) |
2/8 (25.00%) |
6/28 (21.43%) |
0/5 (0.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
19/225 (8.44%) |
Skin and subcutaneous tissue disorders |
|
|
|
|
|
|
|
|
|
Acne |
0/17 (0.00%) |
0/38 (0.00%) |
3/73 (4.11%) |
1/8 (12.50%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
4/225 (1.78%) |
Alopecia |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
1/28 (3.57%) |
1/5 (20.00%) |
0/11 (0.00%) |
5/45 (11.11%) |
8/225 (3.56%) |
Blister |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
1/11 (9.09%) |
0/45 (0.00%) |
1/225 (0.44%) |
Cutaneous vasculitis |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
1/11 (9.09%) |
0/45 (0.00%) |
1/225 (0.44%) |
Decubitus ulcer |
0/17 (0.00%) |
0/38 (0.00%) |
2/73 (2.74%) |
1/8 (12.50%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
3/225 (1.33%) |
Dermatitis |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
1/8 (12.50%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Dermatitis acneiform |
3/17 (17.65%) |
4/38 (10.53%) |
7/73 (9.59%) |
1/8 (12.50%) |
5/28 (17.86%) |
0/5 (0.00%) |
3/11 (27.27%) |
6/45 (13.33%) |
29/225 (12.89%) |
Dry skin |
3/17 (17.65%) |
9/38 (23.68%) |
14/73 (19.18%) |
1/8 (12.50%) |
11/28 (39.29%) |
3/5 (60.00%) |
5/11 (45.45%) |
4/45 (8.89%) |
50/225 (22.22%) |
Eczema |
0/17 (0.00%) |
1/38 (2.63%) |
3/73 (4.11%) |
2/8 (25.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
7/225 (3.11%) |
Eczema asteatotic |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
1/11 (9.09%) |
0/45 (0.00%) |
2/225 (0.89%) |
Hyperhidrosis |
1/17 (5.88%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
2/225 (0.89%) |
Nail ridging |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
1/5 (20.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
3/225 (1.33%) |
Night sweats |
1/17 (5.88%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Onychomadesis |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
1/8 (12.50%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Pain of skin |
1/17 (5.88%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Petechiae |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
1/5 (20.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Pruritus |
4/17 (23.53%) |
11/38 (28.95%) |
27/73 (36.99%) |
5/8 (62.50%) |
12/28 (42.86%) |
3/5 (60.00%) |
6/11 (54.55%) |
9/45 (20.00%) |
77/225 (34.22%) |
Rash |
3/17 (17.65%) |
4/38 (10.53%) |
3/73 (4.11%) |
0/8 (0.00%) |
1/28 (3.57%) |
1/5 (20.00%) |
2/11 (18.18%) |
8/45 (17.78%) |
22/225 (9.78%) |
Rash erythematous |
0/17 (0.00%) |
0/38 (0.00%) |
1/73 (1.37%) |
2/8 (25.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
1/11 (9.09%) |
1/45 (2.22%) |
5/225 (2.22%) |
Rash macular |
1/17 (5.88%) |
1/38 (2.63%) |
5/73 (6.85%) |
0/8 (0.00%) |
4/28 (14.29%) |
2/5 (40.00%) |
0/11 (0.00%) |
2/45 (4.44%) |
15/225 (6.67%) |
Rash maculo-papular |
4/17 (23.53%) |
8/38 (21.05%) |
29/73 (39.73%) |
4/8 (50.00%) |
15/28 (53.57%) |
5/5 (100.00%) |
6/11 (54.55%) |
14/45 (31.11%) |
85/225 (37.78%) |
Rash papular |
0/17 (0.00%) |
1/38 (2.63%) |
2/73 (2.74%) |
1/8 (12.50%) |
3/28 (10.71%) |
0/5 (0.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
8/225 (3.56%) |
Skin discolouration |
1/17 (5.88%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
1/28 (3.57%) |
0/5 (0.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
3/225 (1.33%) |
Skin exfoliation |
1/17 (5.88%) |
1/38 (2.63%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
1/11 (9.09%) |
0/45 (0.00%) |
4/225 (1.78%) |
Skin fissures |
0/17 (0.00%) |
0/38 (0.00%) |
3/73 (4.11%) |
0/8 (0.00%) |
3/28 (10.71%) |
1/5 (20.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
7/225 (3.11%) |
Skin hyperpigmentation |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
1/8 (12.50%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Skin striae |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
1/11 (9.09%) |
0/45 (0.00%) |
1/225 (0.44%) |
Swelling face |
1/17 (5.88%) |
0/38 (0.00%) |
1/73 (1.37%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
2/225 (0.89%) |
Toxic skin eruption |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
1/8 (12.50%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Urticaria |
3/17 (17.65%) |
1/38 (2.63%) |
5/73 (6.85%) |
1/8 (12.50%) |
4/28 (14.29%) |
0/5 (0.00%) |
2/11 (18.18%) |
1/45 (2.22%) |
17/225 (7.56%) |
Vasculitic rash |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
1/8 (12.50%) |
0/28 (0.00%) |
0/5 (0.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Vascular disorders |
|
|
|
|
|
|
|
|
|
Flushing |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
1/5 (20.00%) |
0/11 (0.00%) |
0/45 (0.00%) |
1/225 (0.44%) |
Haematoma |
0/17 (0.00%) |
0/38 (0.00%) |
2/73 (2.74%) |
0/8 (0.00%) |
0/28 (0.00%) |
1/5 (20.00%) |
0/11 (0.00%) |
1/45 (2.22%) |
4/225 (1.78%) |
Hot flush |
0/17 (0.00%) |
0/38 (0.00%) |
0/73 (0.00%) |
0/8 (0.00%) |
0/28 (0.00%) |
0/5 (0.00%) |
1/11 (9.09%) |
0/45 (0.00%) |
1/225 (0.44%) |
Hypertension |
1/17 (5.88%) |
4/38 (10.53%) |
2/73 (2.74%) |
1/8 (12.50%) |
2/28 (7.14%) |
0/5 (0.00%) |
1/11 (9.09%) |
4/45 (8.89%) |
15/225 (6.67%) |
Term from vocabulary, MedDRA (21.0)
Indicates events were collected by systematic assessment
|